News &amp; Updates

The addition of pembrolizumab to the combination of gemcitabine and cisplatin does not appear to worsen the health-related quality of life (HRQoL) in patients with advanced biliary tract cancer (BTC), results of the phase III KEYNOTE-966 study have shown.

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

Long-term cocoa extract supplementation has null effect on hypertension risk in older adults

Taking cocoa extract supplements does not lower the risk of incident hypertension in older adults. However, it does seem to reduce the risk among those who have a normal systolic blood pressure at baseline, according to data from the Cocoa Supplement and Multivitamin Outcomes Study.

Long-term cocoa extract supplementation has null effect on hypertension risk in older adults

Adults with severe asthma may safely perform 6-min walk test

The 6-min walk test appears to be safe for adult patients with severe asthma provided that they receive a bronchodilator medication prior to the test and stop once the blood oxygen saturation levels drop below 85 percent, according to a study.

Adults with severe asthma may safely perform 6-min walk test

Remote AF screening with ECG patch nudges up diagnosis numbers

A remote screening method using a wearable ECG patch yields a modest increase in atrial fibrillation (AF) diagnoses among older adults at risk of stroke, according to the AMALFI trial.

Remote AF screening with ECG patch nudges up diagnosis numbers

Non-White patients are younger at first HF hospitalization: study

Patients identified as non-Hispanic (NH) Asian, NH Black, and Hispanic are younger at the time of first hospitalization for heart failure (HF) than NH White adults in the Get With The Guidelines-Heart Failure (GWTG-HF) registry, according to a study.

Non-White patients are younger at first HF hospitalization: study

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity

17 Sep 2025

Long-term denosumab viable in patients with rheumatic diseases

The use of denosumab for longer durations is generally safe and effective for increasing bone mineral density (BMD) in patients with rheumatic diseases (RDs), suggests a recent study.

Long-term denosumab viable in patients with rheumatic diseases

Screen time in kids, teens tied to cardiometabolic and cardiovascular risks

A study using data from two Danish cohorts demonstrates an association between cardiometabolic risk (CMR) and cardiovascular risk (CVR) and screen time (ST) in children and adolescents, be it through phone, television, or gaming.

Screen time in kids, teens tied to cardiometabolic and cardiovascular risks

Admilparant shows promise in idiopathic, progressive pulmonary fibrosis

The investigational oral lysophosphatidic acid receptor 1 antagonist admilparant helps delay disease progression in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis, according to a phase II trial.

Admilparant shows promise in idiopathic, progressive pulmonary fibrosis

Managing Pompe Disease: From Diagnosis to Enzyme Replacement Therapy

โรคปอมเปย์ (Pompe disease) เป็นโรคพันธุกรรมหายากในกลุ่ม lysosomal storage disease เกิดจากการขาดเอนไซม์ GAA ทำให้สะสมไกลโคเจนในเซลล์กล้ามเนื้อ แบ่งตามช่วงวัยที่แสดงอาการเป็นชนิด infantile-onset Pompe disease (IOPD) และ late-onset Pompe disease (LOPD) การรักษาหลัก คือ การให้เอนไซม์ทดแทน (enzyme replacement therapy; ERT) เช่น ยา avalglucosidase alfa ซึ่งเป็น ERT รุ่นใหม่ที่มีประสิทธิภาพและปลอดภัยทั้งใน IOPD และ LOPD ผลการศึกษาทางคลินิก พบว่า ยา avalglucosidase alfa ช่วยพัฒนาสมรรถภาพปอดในผู้ป่วย LOPD ได้ไม่ด้อยกว่า ERT รุ่นแรก และช่วยให้ผู้ป่วย IOPD ที่เปลี่ยนมาใช้ยามีกำลังกล้ามเนื้อคงที่หรือดีขึ้น รวมทั้งไม่เพิ่มความเสี่ยงต่อการแพ้ยา

Managing Pompe Disease: From Diagnosis to Enzyme Replacement Therapy